n and CEO, noted, "The tissue engineering market is highly strategic for BioLife. Our products have great potential to resolve the current cell yield and shelf-life issues that often limit large scale commercialization and clinical distribution of new biologic-based therapies. We currently supply CryoStor and HypoThermosol(R) to several start-up customers and support product evaluations at other key companies in the tissue engineering market."
According to a 2009 analysis and report by Life Science Intelligence, the largely untapped global market potential for tissue engineering and regenerative medicine products will exceed $118 billion by 2013. The actual current market, which represents only a fraction of the potential market, was estimated at $1.5 billion in 2008. The report forecasts rapid growth driven by various factors including increased adoption in various clinical areas and international market trends.
About BioLife Solutions, Inc.:
BioLife Solutions develops and markets patented hypothermic storage/transport and cryopreservation media products for cells, tissues, and organs. The Company's proprietary HypoThermosol(R) and CryoStor(TM) platform of biopreservation media products are marketed to academic research institutions, hospitals, and commercial companies involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife's cGMP products are serum-free and protein-free, fully defined, and formulated to reduce preservation-induced, delayed-onset cell damage and death. BioLife's enabling technology provides research and clinical organizations significant improvement in post-preservation cell and tissue viability and function. For more information please visit www.biolifesolutions.com.
About IBET- Instituto de Biologia Experimental e Tecnologica:
Page: 1 2 3 4 Related biology technology :1
|SOURCE BioLife Solutions, Inc.|
Copyright©2009 PR Newswire.
All rights reserved
. Waters Corporation Continues to Meet Todays Challenges for Improved Laboratory Operations with New Products at Pittcon 20092
. New Study Reports Improved Patient Outcomes for Breast Cancer Patients3
. Avantis Medical Systems Announces FDA 510(k) Clearance for the Third Eye(R) Retroscope(R) for Improved Polyp Detection in the Colon4
. Research highlights potential for improved solar cells5
. A need for improved efficiency in nanomanufacturing6
. One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study7
. In-Room Computers and Wall-Mounted Proximity Systems Computer WorkStations Deliver Increased Efficiency; Improved Patient Care8
. Finesse Solutions Launches Improved E-Store for Sensors and Transmitters9
. Kelly Osbourne and International Health Groups Call for Improved Education on Choices and Usage of Contraception10
. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice11
. Improved culture system for hepatitis C virus infection